Analysts Set bluebird bio Inc (BLUE) Target Price at $193.76

bluebird bio Inc (NASDAQ:BLUE) has been assigned a consensus recommendation of “Hold” from the twenty-six analysts that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $193.76.

Several brokerages have recently weighed in on BLUE. Canaccord Genuity reissued a “buy” rating and set a $250.00 target price on shares of bluebird bio in a research report on Thursday, February 1st. Maxim Group reissued a “hold” rating and set a $200.00 target price on shares of bluebird bio in a research report on Thursday, February 22nd. Morgan Stanley reissued an “equal weight” rating and set a $152.00 target price (up previously from $151.00) on shares of bluebird bio in a research report on Monday, February 26th. William Blair reissued a “buy” rating on shares of bluebird bio in a research report on Friday, March 16th. Finally, CIBC began coverage on bluebird bio in a research report on Thursday, December 21st. They set a “market perform” rating on the stock.

How to Become a New Pot Stock Millionaire

Shares of BLUE stock traded down $9.45 during trading hours on Friday, hitting $160.70. 326,834 shares of the company’s stock were exchanged, compared to its average volume of 870,364. The company has a market cap of $8,652.15, a price-to-earnings ratio of -20.84 and a beta of 2.16. bluebird bio has a fifty-two week low of $74.45 and a fifty-two week high of $236.17.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The business had revenue of $4.17 million for the quarter, compared to analyst estimates of $7.11 million. During the same period in the previous year, the company earned ($1.88) earnings per share. The company’s quarterly revenue was up 169.0% compared to the same quarter last year. research analysts forecast that bluebird bio will post -8.39 EPS for the current year.

In related news, COO Susanna Gatti High sold 17,262 shares of bluebird bio stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total value of $3,381,798.42. Following the sale, the chief operating officer now directly owns 28,512 shares in the company, valued at $5,585,785.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Jason Cole sold 25,000 shares of bluebird bio stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total value of $4,897,750.00. Following the completion of the sale, the insider now owns 44,798 shares in the company, valued at $8,776,376.18. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 80,034 shares of company stock worth $15,122,163. Company insiders own 3.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of BLUE. Prudential Financial Inc. raised its stake in bluebird bio by 12.6% during the third quarter. Prudential Financial Inc. now owns 4,372 shares of the biotechnology company’s stock valued at $600,000 after buying an additional 490 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of bluebird bio by 52.0% during the 3rd quarter. Principal Financial Group Inc. now owns 69,185 shares of the biotechnology company’s stock worth $9,503,000 after purchasing an additional 23,682 shares during the period. BNP Paribas Arbitrage SA raised its position in shares of bluebird bio by 6.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,444 shares of the biotechnology company’s stock worth $748,000 after purchasing an additional 330 shares during the period. Bank of New York Mellon Corp raised its position in shares of bluebird bio by 7.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 245,563 shares of the biotechnology company’s stock worth $33,729,000 after purchasing an additional 17,449 shares during the period. Finally, Comerica Bank acquired a new stake in shares of bluebird bio during the 3rd quarter worth approximately $242,000.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3335569/analysts-set-bluebird-bio-inc-blue-target-price-at-193-76.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head-To-Head Analysis: Omni Lite Industries Canada  vs. Park-Ohio
Head-To-Head Analysis: Omni Lite Industries Canada vs. Park-Ohio
Reviewing Caladrius Biosciences  & Tivity Health
Reviewing Caladrius Biosciences & Tivity Health
Comparing Pacific Ethanol  and Its Peers
Comparing Pacific Ethanol and Its Peers
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Capital Product Partners  Share Price
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Capital Product Partners Share Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Del Taco Restaurants  Share Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Del Taco Restaurants Share Price
Blue Apron  Receiving Somewhat Favorable Press Coverage, Report Shows
Blue Apron Receiving Somewhat Favorable Press Coverage, Report Shows


© 2006-2018 Ticker Report. Google+.